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Abstract
The high-throughput, label-free Corning Epic assay has applications in drug discovery,
pharmacogenomics, cell receptor signaling, cell migration, and viral titration. The utility of
Epic technology for biocompatibility testing has not been well established. In manufacturing
of medical devices, in vitro and in vivo biocompatibility assessments are mandatory, accord-
ing to ISO 10993. The newmedical device regulationMDR 745/2017 specifies that ex vivo
assays that can closely recapitulate in vivo scenarios are needed to better evaluate biomedi-
cal devices. We propose herein that Epic technologyÐwhic h enables detection of variations
in cell mass distributionÐis suitable for biocompatibility screening of compounds. In this
study, we challenged primary human osteoblasts, endothelial cells, and neurons derived
from induced pluripotent stem cells with specific concentrations of methyl methacrylate
(MMA). Polymeric MMA has long been applied in cranioplasty, where it makes contact with
multiple cell types. Application of Epic technology yielded real-time cytotoxicity profiles for
all considered cell types. The results were compared with those frommicroscopic observa-
tion of the same culture plate used in the Epic analyses. The Epic assay should be further
examined for its utility for cell biology, genomics, and proteomics companion assays. Our
results suggest that Epic technology can be applied to biocompatibility evaluation of human
cells in medical device development.
Introduction
Medical devices in development must be evaluated for biocompatibility in accordance with
ISO 10993 [1]. This includes cytotoxicity and in vivo tests, such as irritation, intracutaneous
reactivity, and sensitization, for all classes of medical devices [2,3,4]. To ascertain cytotoxicity,
ISO 10993±5mandates use of the methylthiazolyl tetrazolium (MTT) assay with 3T3 or L929
murine cells cultured with extracts derived from test samples, obtained according to ISO
10993±12 [5]. In the MTT assay, tetrazolium salt is added to cells in culture; the salt is reduced
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by viable cells into a colored formazan, which is quantifiable by a colorimetric measurement
[6]. However, the MTT assay has several limitations, the most important being that tetrazo-
lium is toxic to cells. Therefore, the MTT assay must be undertaken with separate cell culture
plates for each time point [7,8,9]. This assay also is associated with a long incubation time (up
to 4 hours) prior to colorimetric detection. Thus, the initial cell response cannot be observed
with this method [6].
Epic label-free technology (Corning, Tewksbury, MA) has been described as a means of cell
phenotypic screening in drug discovery [10,11] and may be suitable for analyses of biocompat-
ibility. The Epic assay is noninvasive and is performed by placing native cells onto optical bio-
sensors embedded in each well of a microplate [12]. The assay results specify the dynamic
mass redistribution (DMR)Ðthat is, variations in the steric distribution of cell massÐin pic-
ometers (pm) [13]. An increase in raw signal (response) is correlated with a volumetric
increase and is denoted as a positive-DMR (P-DMR). Conversely, a decrease in response is
associated with cell shrinkage and is reported as a negative-DMR (N-DMR; Fig 1) [14,15]. The
temporal sequence of all DMR phases generates a phenotypic profile for the corresponding cell
population.
In toxicologic studies involving the Epic assay, shrinkage associated with apoptosis yields
an N-DMR profile, which indicates toxicity (Fig 1A) [16]. Cell swelling, associated with cell
necrosis, may produce assay results of a P-DMR followed by an N-DMR, with the latter indi-
cating cell membrane degradation [17]. Appropriate controls are included in an Epic analysis
at specific time points to discriminate nontoxic from toxic compounds. The former produces
a response similar to that of the negative control, whereas the latter generates results similar to
that of the positive control (Fig 1B).
Epic label-free technology can be applied to diverse fields, including agonist-antagonist
assays, identification of cytotoxic agents, and drug development in pharmacology [18,19].
The use of the Epic assay to evaluate biocompatibility of medical devices has not been
explored previously. Pikis et al. evaluated a series of 6 patients who experienced neuronal dys-
function after polymethyl methacrylate (PMMA) cranioplasty; these authors noted that neuro-
toxicity could be related to the release of the methyl methacrylate (MMA) monomer during
implantation of the cranial prosthesis [20]. Herein, we applied Epic technology to ascertain the
biocompatibility of MMA in multiple cell types: primary human adherent endothelial cells,
osteoblast lines, and neurons derived from induced pluripotent stem cells (i.e., iPS-derived
neurons). Our results demonstrate that biocompatibility analyses of medical devices are feasi-
ble with the Epic assay. In our hands, Epic label-free technology was sufficiently sensitive to
potentially allow for customized assays of human cells.
Materials andmethods
Cell cultures
Primary human osteoblasts and HUVECs, as mesenchymal cells, were used to represent bone
and blood vessels, respectively. Primary human osteoblasts and all cell culture reagents were
purchased from PromoCell (Heidelberg, Germany). HUVECs were purchased from Promo-
Cell, and all cell culture reagents were obtained from Gibco (Life Technologies, Paisley, UK).
For neuronal tissue, we used iPS-derived neurons (iCell i-Neurons; Cellular Dynamics Inter-
national, Madison, WI).
Primary human osteoblasts were thawed and subcultured, per the manufacturer's instruc-
tions. Cells were incubated for 2 minutes in a water bath at 37ÊC,and a suspension of approxi-
mately 500,000 cells/vial was transferred to a cell culture flask at a density of 20,000 cells/cm2.
The flask had been prefilled with growth medium (PromoCell) and kept in an incubator at
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37ÊCand 5% CO2. The medium was replaced 24 hours after thawing and every 3 days thereaf-
ter. At 90% confluency, osteoblasts were detached with a solution of trypsin and Ethylenedi-
aminetetraacetic acid (EDTA) (DetachKit, PromoCell) for 3 minutes at room temperature.
Fetal bovine serum (FBS) was added to inactivate the trypsin, and cells were seeded in media
at 10,000 cells/cm2. At passage 7, cells were detached and seeded at 6000 cells/well into a label-
free 96-well microplate (PerkinElmer, Waltham, MA) for cytotoxicity assays.
After thawing, 300,000 HUVECs were resuspended in M200 basal medium supplemented
with an LSGS (i.e., low serum growth supplement) kit comprising 2% FBS, 3 ng/mL of rh-
bFGF (i.e., recombinant human basic fibroblast growth factor), 10 µg/mL of heparin, 100 µg/
mL of bovine serum albumin (BSA), 1 µg/mL of hydrocortisone, 10 ng/mL of rh-EGF (i.e.,
recombinant human epidermal growth factor), 10 µg/mL of gentamicin, and 0.25 µg/mL of
amphotericin B. Cells were seeded into flasks precoated with an attachment factor (AF, pur-
chased by Gibco) at a density of 4000 cells/cm2. The AF was added to the flask and kept at
37ÊCfor 30 minutes, than it was discarded and the flask was washed with PBS 1x. The medium
was replaced 24 hours after thawing and every 3 days thereafter. At 90% confluency, HUVECs
were detached by treatment with trypsin/EDTA for 5 minutes at room temperature. FBS was
added for trypsin inactivation and washing, and cells were seeded into precoated flasks at a
density of 4000 cells/cm2. Cells then were amplified for several passages. At passage 7, cells
were detached and seeded at a density of 9000 cells/well into a label-free 96-well microplate
(PerkinElmer) for cytotoxicity assays.
For cytotoxicity assays involving human iPS-derived neurons, label-free 96-well sensor
microplates (PerkinElmer) were coated with a base layer of poly-L-ornithine and an upper
layer of laminin (both, Sigma, Milan, Italy). Complete Maintenance Medium (Cellular
Dynamics International) then was added to wells, and iPS-derived neurons were thawed and
immediately seeded at a density of 30,000 cells/well.
Label-free cytotoxicity assay
In cytotoxicity studies with the Epic assay, the negative control (nontoxic compound) was
0.2% DMSO, and the positive control (toxic compound) was 0.1% SDS. Seven time points
were considered: 1 minute, 20 minutes, and 1, 2, 4, 8, and 24 hours. Concurrently, continuous-
mode readings were taken for all cell types at a frequency of 1 read every 5 minutes to investi-
gate the early-stage phenotypic profile (i.e., within the first hour).
Fig 1. Cell phenotypic profile results of the Epic label-free assay, and implications for toxicology testing. Fig 1A:
After administration of the compound, a positive-dynamic mass redistribution (P-DMR) indicated an increase in the
cell response and correlated with augmented cell size. Conversely, a decrease in the cell response was observed as a
negative-dynamic mass redistribution (N-DMR) and correlated with cell shrinkage. Fig 1B: The difference in response
(Δ) between the negative (green circle) and positive controls (red circle) enabled discrimination of nontoxic
compounds (i.e., similar to the negative control) from toxic compounds (i.e., similar to the positive control).
https://doi.org/10.1371/journal.pone.0201671.g001
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Cells were seeded in single wells containing 120 µL of specific culture media, and MMA
(Tecres SpA, Verona, Italy) was added at a concentration of 250, 550, or 700 µg/cm2. Twenty-
four hours after seeding, cells were washed 4 times using 49 µL of an assay buffer prepared
from a cell-specific complete culture medium diluted 1:1 with double-distilled water. Washing
was carried out using an aspiration wand (VP 185-L, V&P Scientific, San Diego, CA), and a
final volume of 80 µl/well of assay buffer was reached. The loaded microplates were covered
with a permeable film membrane (SealMate AeraSeal; Excel Scientific, St. Louis, MO) and
were equilibrated at 37ÊCand 5% CO2 for 2 hours. After incubation, an initial baseline reading
was taken for 5 minutes, and 20 µL/well of each tested compound (at 5× concentration) was
transferred to cell-loaded label-free microplates as follows: (1) assay buffer (blank sample), (2)
0.1% SDS in assay buffer (v/v, final concentration; positive cytotoxic control), (3) 0.2% DMSO
in assay buffer (v/v, final concentration; negative nontoxic control), and (4) MMA at the pre-
specified concentrations in assay buffer.
Immediately after compound addition, the plates were gently mixed with an IncuShaker
Mini (Memmert, Schwabach, Germany) at 75 rpm for 30 seconds. Plates then were loaded
into the Enspire Multimode Plate Reader (PerkinElmer), and final readings were taken
sequentially at 5 time points: (1) 1 to 60 minutes (1 read repeat/minute), (2) 1.50 to 2 hours (1
read repeat/minute), (3) 3.50 to 4 hours (1 read repeat/minute), (4) 7.50 to 8 hours (1 read
repeat/minute), and (5) 23.55 to 24.05 hours (1 read repeat/minute). Between reads, cells were
kept in an incubator to promote CO2 intake and humidity equilibration. All baseline and final
reads were made in a preheated Enspire multiplate reader at 37ÊC.
Statistical analysis
Data were exported into Microsoft Excel 2013 (Redmond, WA). Background DMR (i.e., cell
responses to assay buffer) were subtracted from all datasets, as described previously [21]. DMR
data (n = 6 replicates/each condition) were expressed as mean ± standard error of the mean
(SEM) and were plotted in a 2-dimensional (2D) dispersion graph. All graphs were generated
using Graph Pad Prism 6 software (La Jolla, CA). Hyperbolic 1-phase decay graphs were evalu-
ated using the curve-fitting function on Graph Pad. The plateau and span of the hyperbolic
curve were expressed as mean ± standard deviation (SD).
Assay validation (robustness) was assessed by a Z'-factor calculation, in which c+ is the pos-
itive cytotoxic control (0.1% SDS), and c- is the negative nontoxic control (0.2% DMSO):
Z0 ¼ 1  
3ðscþ þ sc  Þ
jmcþ   mc  j
A z'  0.5 was regarded as an excellent (i.e., highly robust) assay. Cellular responses to the
compounds were evaluated for significant differences at each time point by means of 1-way
ANOVA (Excel 2013). The effects of compound type and incubation time on the cell response
were evaluated using 2-way ANOVA (Excel 2013). Statistical significance was defined as
p< 0.05.
Results and discussion
Fig 2 depicts Epic assay findings involving 2 mesenchymal-derived cell types: osteoblasts and
human umbilical vein endothelial cells (HUVECs). Cells exposed to sodium dodecyl sulfate
(SDS)Ðthe positive cytotoxic controlÐexhibited a progressive reduction in response, relative
to the basal level for each cell type (−0.2 ± 2.1 pm and 1.7 ± 1.1 pm for osteoblasts and
HUVECs, respectively; baseline data not shown). The response of these cells to SDS adhered to
a model of exponential decay (Fig 2A and 2E). Specifically, the raw data was fitted to a
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Fig 2. Effects of MMA on osteoblasts and HUVECs.A label-free assay (Epic, Corning) of cell response was carried
out using 0.2% DMSO as the negative control and 0.1% SDS as the positive control. Osteoblasts and HUVECs were
exposed to 3 concentrations of MMA: 250 µg/cm2, 550 µg/cm2, and 700 µg/cm2. Fig 2A±2D: Results of the Epic assay
on osteoblasts. Fig 2A: The phenotypic profile of osteoblasts exposed to 0.1% SDS resembles a model of exponential
decay and was specified as a hyperbolic 1-phase decay curve in GraphPad software. The red inset displays features of
the osteoblasts 24 hours after SDS administration. Note the complete detachment of cells from the plastic. Fig 2B:
Multiple time point measurement findings were plotted in a 2D dispersion graph, with relative z'-factor analysis
(n = 6). MMA-treated cells exhibited a range of responses comparable to those of DMSO-treated cells. Hence, the
monomer was nontoxic to these cells. Fig 2C: Representative photomicrographs of osteoblasts treated with 0.2%
DMSO or with MMA at 1 of the 3 specified concentrations. After 24 hours, both DMSO-treated and MMA-treated
samples displayed normal cell morphologies, indicating a lack of toxicity. Fig 2D: Phenotypic profile analysis of
osteoblasts treated with DMSO or MMA.Within 20 minutes, MMA-treated osteoblasts displayed a response
comparable to those treated with DMSO. At 60 minutes, the responses to MMA differed in a dose-dependent manner
(1-way ANOVA; p< 0.05). Fig 2E±2H: Results of the Epic assay in HUVECs (endothelial cells). Fig 2E: The
phenotypic profile of HUVECs exposed to 0.1% SDS resembled a model of exponential decay and was specified as a
hyperbolic 1-phase decay curve by GraphPad software. The red inset depicts features of the HUVECs 24 hours after
SDS administration. Note the complete lack of plastic-adhering cells. Fig 2F:Multiple time point measurement results
were plotted in a 2D dispersion graph, with relative z'-factor analysis (n = 6). MMA-treated cells showed a range of
responses comparable to those of DMSO-treated cells. Therefore, the MMAmonomer is nontoxic in these cells. Fig
2G: Representative photomicrographs of HUVECs treated with 0.2% DMSO or MMA at 1 of the 3 specified
concentrations. After 24 hours, both DMSO-treated and MMA-treated samples displayed normal cell morphologies,
indicating a lack of toxicity. Fig 2H: Phenotypic profile analysis of HUVECs treated with DMSO or MMA. For all
MMA concentrations tested, HUVEC responses were comparable and differed statistically from those of DMSO-
treated cells at 20- and 60-minute time points (1-way ANOVA; p< 0.05).
https://doi.org/10.1371/journal.pone.0201671.g002
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hyperbolic 1-phase decay curve with a plateau of −685.3 ± 13.5 pm and −998.7 ± 37.2 pm for osteo-
blasts and HUVECs, respectively. This curve was associated with a span of 579.4 ± 36.9 pm and
376.1 ± 90.1 pm for osteoblasts and HUVECs, respectively (Fig 2A and 2E), suggesting a greater
sensitivity of osteoblasts toMMA. This trend was associated with complete cell death in both cell
lines, as confirmed by massive cell detachment at the 24-hour endpoint (Fig 2A and 2E; red inset).
Dimethyl sulfoxide (DMSO)-treated cells had negligible cytotoxicity for all time points eval-
uated (Fig 2B and 2F). In both osteoblasts and HUVECs, 1 hour after exposure to the com-
pound, the Epic assay results enabled discrimination between a DMSO-like response
(nontoxic) and an SDS-like response (toxic). Assay results yielded a z'-factor that indicated
when assay validation was excellent (i.e., highly robust), based on a pre-established cut off of
z'0.5; Fig 2B and 2F [22]. Findings of multipoint time analyses revealed that the assay was
optimized within 1 hour from the administration of the stimulating compound. Thus, unlike
the MTT assay, the Epic assay is not limited by a long incubation and a single read-out time.
At all time points, MMA-treated osteoblasts and HUVECs showed a range of responses
that was comparable to those of cells treated with DMSO (i.e., DMSO-like profile; S1 Fig 2B,
S2 Fig 2B, S3 Fig 2F and S4 Fig 2F). These findings were confirmed by microscopy results after
24 hours of incubation: both DMSO-treated and MMA-treated samples displayed a cell mor-
phology indicative of a lack of toxic effect (Fig 2C and 2G). At 24 hours, the responses of osteo-
blasts to MMA treatment varied in a dose-dependent manner that was small but statistically
significant (Fig 2B; 2-way analysis of variance [ANOVA]; Table 1A). This supported the
hypothesis that Epic label-free technology was sufficiently sensitive to detect a biological effect
in human primary cells. Statistically significant differences in cellular responses among incu-
bation times also were found for osteoblasts and HUVECs treated with 0.2% DMSO or with
MMA at 250, 550, or 700 µg/cm2 (p< 0.05; Table 1A). These data indicate a cellular reaction
that may not necessarily be related to cytotoxicity but to a biological effect that should be fur-
ther explored with multimodal approaches.
Table 1. Effects of compound type and incubation time on cellular responses.
A
OSTEOBLAST
SOURCE F-value p-Value
INCUBATION TYPE + COMPOUNDTYPE 3,3 4,2 x 10−5
INCUBATION TYPE 14,1 1,1 x 10−12
COMPOUNDTYPE 3,3 2 x 10−2
B
HUVEC
SOURCE F-value p-Value
INCUBATION TYPE + COMPOUNDTYPE 2,1 9 x 10−3
INCUBATION TYPE 8,9 2,7 x 10−8
COMPOUNDTYPE 13,1 1,4 x 10−7
C
NEURON
SOURCE F-value p-Value
INCUBATION TYPE + COMPOUNDTYPE 1,8 3 x 10−2
INCUBATION TYPE 15,1 2,6 x 10−13
COMPOUNDTYPE 70,5 7,5 x 10−28
A-C: Two-way ANOVAwas applied to data analyses for all cell types. Compounds and incubation times, as well as
the interactions of these factors, influence the responses of osteoblasts, HUVECs, and iPS-derived neurons.
https://doi.org/10.1371/journal.pone.0201671.t001
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We next performed a detailed examination of the responses to DMSO (negative control)
and MMA (test compound), as recorded in raw form for osteoblasts and HUVECs by continu-
ous-mode reading within 1 hour of compound administration (Fig 2D and 2H). DMSO-
treated cells showed a cell type±dependent phenotypic profile. Osteoblasts displayed a profile
involving an early N-DMR curve followed by restoration of the response to basal levels (Fig
2D). Osteoblasts treated with MMA had a response comparable to those treated with DMSO
within the first 20 minutes. At 60 minutes post administration, the responses of osteoblasts to
MMA differed in a dose-dependent manner (1-way ANOVA; p = 8.1 × 10−5). However,
HUVECs treated with DMSO had an early N-DMR peak following by a P-DMR curve (Fig
2H). HUVECs treated with MMA at any of the 3 tested concentrations exhibited comparable
responses that statistically differed from cells treated with DMSO at 20 and 60 minutes (1-way
ANOVA; p = 6 × 10−4 and p = 3 × 10−3 for 20 minutes and 60 minutes, respectively). These
findings indicate that osteoblasts and HUVECs have a DMSO-like cell profile when exposed to
MMA. Thus, the monomer should be regarded as nontoxic at the tested concentrations (Fig
2D and 2H).
We next applied the Epic assay to explore the effects of MMA on an ectodermal cell type:
iPS-derived neurons (Fig 3). These neurons displayed a very early positive response starting
from 1 minute after compound addition (262.6 ± 9.6 pm), relative to the baseline response of
0.3 ± 0.4 pm (data not shown). From 1 minute to 24 hours, iPS-derived neurons showed a pro-
gressive reduction in response that adhered to a model of exponential decay (Fig 3A). The raw
data were fitted to a hyperbolic 1-phase decay curve with a plateau of −113.8 ± 27.7 pm associ-
ated with a span of 343 pm (Fig 3A). This trend, contrary from that of osteoblasts and
HUVECs, was not associated with complete cell detachment. Instead, iPS-derived neurons
exhibited an increase in cell volume and deterioration of the cell membrane (Fig 3A, red
inset). Conversely, DMSO-treated control neurons displayed negligible cytotoxicity for all
time points (Fig 3B).
The iPS-derived neurons treated with prespecified concentrations of MMA showed a range
of responses comparable with that of cells treated with DMSO (i.e., DMSO-like profile; S5 Fig
3B and S6 Fig 3B). These findings were confirmed after 24 hours by microscopic observation
(Fig 3C). Both DMSO-treated and MMA-treated samples had cell morphologic findings indic-
ative of a lack of toxicity (Fig 3C). Nevertheless, the 2-way ANOVA results showed a signifi-
cant difference among cells that were exposed to 0.2% DMSO or to 250, 550, or 700 µg/cm2 of
MMA (p< 0.05; Table 1C). As with results of osteoblasts and HUVECs exposed to MMA,
these data do not necessarily indicate a toxic effect of MMA, but rather uncharacterized bio-
logical effects.
We then undertook an analysis of continuous-mode readings of the raw responses of iPS-
derived neurons exposed to DMSO or MMA during the first 1 hour of the assay (Fig 3D).
DMSO-treated neurons exhibited a unique phenotypic profile, with an early and low N-DMR
curve, followed by restoration of the response to basal levels (Fig 3D). All MMA-treated iPS-
derived neurons showed comparable responses that differed statistically from those of DMSO-
treated cells at 1 hour (1-way ANOVA; p = 4.8 × 10−6). This finding confirms that the mono-
mer is nontoxic to neuronal cells (Fig 3D).
Corning's Epic label-free technology may be suitable for a broad range of applications,
including drug discovery, pharmacogenomics, cell receptor signaling, cell migration, and viral
titration [11,23,24,25]. To our knowledge, this study is the first to address the application of
the Epic assay to biocompatibility testing of the MMAmonomer on human osteoblasts,
human endothelial cells, and iPS-derived neurons. Our data demonstrate that the MMA
monomer, at the tested concentrations, is nontoxic to primary and iPS-derived human cells.
Label-free toxicology screening of primary humanmesenchymal cells and iPS-derived neurons
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These findings support the in vitro biocompatibility of MMA as a material for cranioplasty
implantation [26].
The MTT assay requires a long incubation time, which precludes observation of the early-
stage biological response. In contrast, Epic label-free technology generates results immediately
after contact between cells and the stimulant. The Epic assay allows the investigator to rapidly
evaluate the impact of a compound on specific cell types. Epic technology is sufficiently sensi-
tive to detect subcytotoxic biological events that would not be detectable by microscopy or
standard cytotoxicity assays. By enabling detection of the earliest hallmarks of a specific cellu-
lar response to a molecule, the Epic assay can help to focus and facilitate follow-up studies
involving mRNA or miRNA expression profiling, electron microscopy, or proteomics. A com-
bination of an initial Epic screen and these other modalities could minimize issues of oversen-
sitivity associated with the Epic assay and could open a new field of the very early signs of
cellular response to specific agents.
Fig 3. Effects of MMA on iPS-derived neurons, ascertained by the Epic label-free assay. The Epic label-free assay was carried
out on iPS-derived neurons, with 0.2% DMSO and 0.1% SDS as negative and positive controls, respectively. Neurons were
exposed to 1 of 3 concentrations of MMA: 250 µg/cm2, 550 µg/cm2, or 700 µg/cm2 of the cell layer surface. Fig 3A: The phenotypic
profile of iPS-derived neurons exposed to 0.1% SDS resembled a model of exponential decay. Within 1 minute after SDS addition,
iPS-derived neurons responded with an early P-DMR. The red inset indicates features of the iPS-derived neurons 24 hours after
SDS administration. Note the increase in cell volume (indicated by arrowheads) and the appearance of ruffling cell membranes
(indicated by arrows). Fig 3B: Multiple time point measurement findings were plotted in a 2D dispersion graph, with relative z'-
factor analysis (n = 6). The early P-DMR for SDS-treated neurons was associated with a robust z' factor (z 0.5) at 1 minute and
after 24 hours. MMA-exposed cells exhibited a range of responses that was comparable to those administered DMSO. Hence,
MMA was nontoxic to these cells at the tested concentrations. Fig 3C: Representative photomicrographs of cells treated with 0.2%
DMSO or MMA. After 24 hours, DMSO-treated and MMA-treated samples exhibited normal morphologic characteristics, which
indicated a lack of toxicity. Fig 3D: Phenotypic profile analysis of iPS-derived neurons treated with DMSO or MMA. At 60
minutes, iPS-derived neurons treated with prespecified concentrations of MMA exhibited responses that were comparable to each
other and that differed significantly from those of DMSO-treated cells (1-way ANOVA; p< 0.05).
https://doi.org/10.1371/journal.pone.0201671.g003
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Conclusion
In our study, we propose a cellular model using three different tissue-specified cell types in a
label free manner (bone derived cells, endothelial derived cells and neuron-like cells). We
applied the Epic Label Free technology in the field of biocompatibility of medical devices: it is
able to discriminate the toxic nature of the SDS compared to the nontoxic DMSO compound.
After the definition of the cell response to proper controls, we were able to evaluate the cellular
response to MMA by comparing its profile within controls.
Our results support the further development of Epic label-free technology for biocompati-
bility studies, in which unlabeled, tissue-specific human cells may be challenged with medical
devices in development for validation of the intended use and to obtain more comprehensive
in vitro data on safety, as required by the new medical device regulation [27].
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